BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
Treatment of Ph-negative ALL in adolescents and young adults
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Treatment of Ph-negative ALL in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The new era of ALL treatment ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
Safety considerations for inotuzumab in patients with relapsed/refractory ALL
Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, U...
Safety considerations for inotuzumab in patients with relapsed/refractory ALL ( Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
23 Jan 2020
Identifying cancer susceptibility genes in paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Identifying cancer susceptibility genes in paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Defining high-risk acute lymphoblastic leukaemia
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Defining high-risk acute lymphoblastic leukaemia ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Latest concepts in frontline therapy for paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Are remissions for AML patients 'better' after daunorubicin and cytarabine lipos...
Prof Daniel Ryan - University of Rochester, Rochester, USA
Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML patien...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible newly...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019